SNY
Sanofi
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-33/100
Last price
39.88
▲ 0.37 (0.94%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
39.79
Prev close
39.51
Day high
40.04
Day low
39.24
Volume
3.05M
Market cap
$94.79B
P/E (TTM)
20.82
52W range
39.18 – 52.68
Day trading desk
Gap from prior close
+0.71%
Prior close 39.51
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
0.33%
39.79 – 39.92
Position in range
69%
Mid range
ATR (14D)
0.75
1.88% of price
Prior day high
39.88
PDH
Prior day low
39.18
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 2.88M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.90%
-4.8%
1M
-10.58%
-11.7%
3M
-7.53%
-12.0%
6M
-15.52%
-33.7%
YTD
-18.37%
-32.6%
1Y
-22.28%
-38.7%
3Y
-26.25%
-108.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SNY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
23.96K
Total on file
Fundamentals
Market cap$94.79B
Enterprise value$112.38B
Revenue (TTM)$48.92B
Gross profit$35.93B
EBITDA$13.54B
Net income$3.94B
EPS (TTM)$1.90
Free cash flow$6.30B
Total cash$6.35B
Total debt$23.58B
Book value / share$33.60
Shares outstanding2.40B
Float2.16B
Short % of float0.44%
Dividend yield6.11%
Beta (5Y)0.28
Valuation & profitability ratios
Trailing P/E20.82
Forward P/E7.32
PEG ratio27.13
Price / sales—
Price / book1.18
EV / revenue2.30
EV / EBITDA8.30
Gross margin73.45%
Operating margin21.03%
Profit margin8.09%
Return on equity5.71%
Return on assets5.09%
Debt / equity33.89
Current ratio0.99
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $46.72B | $44.29B | $41.62B | $40.56B | +5.5% |
| Operating revenue | $43.63B | $41.08B | $37.82B | $37.65B | +6.2% |
| Cost of revenue | $13.05B | $13.21B | $12.63B | $11.88B | -1.2% |
| Gross profit | $33.67B | $31.08B | $28.99B | $28.68B | +8.3% |
| Research & development | $7.84B | $7.39B | $6.51B | $6.50B | +6.1% |
| Selling, general & admin | $10.24B | $9.82B | $9.48B | $8.74B | +4.3% |
| Total operating expense | $24.07B | $22.16B | $20.30B | $17.75B | +8.6% |
| Operating income | $9.60B | $8.92B | $8.69B | $10.93B | +7.6% |
| Net interest income | -$129.00M | -$490.00M | -$626.00M | -$223.00M | +73.7% |
| Pre-tax income | $6.17B | $6.70B | $6.25B | $9.94B | -7.8% |
| Tax provision | $1.04B | $1.20B | $1.02B | $1.91B | -13.4% |
| Net income | $7.81B | $5.56B | $5.40B | $8.37B | +40.5% |
| Net income to common | $7.81B | $5.56B | $5.40B | $8.37B | +40.5% |
| Basic EPS | 3.20 | 2.30 | 2.16 | 2.69 | +39.4% |
| Diluted EPS | 3.19 | 2.30 | 2.16 | 2.69 | +38.8% |
| EBIT | $6.80B | $7.40B | $6.89B | $10.40B | -8.1% |
| EBITDA | $12.48B | $10.99B | $11.32B | $13.51B | +13.6% |
| Basic shares | 2.44B | 2.50B | 2.50B | 2.50B | -2.5% |
| Diluted shares | 2.45B | 2.50B | 2.50B | 2.50B | -2.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $7.66B | $7.44B | $8.71B | $12.74B | +2.9% |
| Cash & short-term investments | $8.47B | $7.93B | $8.98B | $13.40B | +6.8% |
| Accounts receivable | $8.41B | $7.68B | $8.43B | $8.42B | +9.5% |
| Inventory | $10.21B | $9.43B | $9.67B | $8.96B | +8.3% |
| Total current assets | $30.95B | $42.59B | $30.67B | $34.11B | -27.3% |
| Property, plant & equipment | $11.51B | $11.60B | $11.81B | $11.68B | -0.8% |
| Goodwill & intangibles | $67.56B | $66.01B | $73.72B | $71.53B | +2.3% |
| Total assets | $126.81B | $132.80B | $126.46B | $126.72B | -4.5% |
| Total current liabilities | $28.34B | $29.16B | $24.21B | $23.97B | -2.8% |
| Current debt | $4.34B | $4.21B | $2.04B | $4.17B | +3.2% |
| Long-term debt | $14.25B | $11.79B | $14.35B | $14.86B | +20.8% |
| Total debt | $20.33B | $17.91B | $18.42B | $21.21B | +13.5% |
| Total liabilities | $55.09B | $54.94B | $52.11B | $51.57B | +0.3% |
| Shareholder equity | $71.38B | $77.51B | $74.04B | $74.78B | -7.9% |
| Working capital | $2.61B | $13.43B | $6.46B | $10.14B | -80.6% |
| Net tangible assets | $3.81B | $11.49B | $317.00M | $3.25B | -66.8% |
| Shares issued | 1.22B | 1.26B | 1.26B | 1.27B | -3.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $4.94B | $5.50B | $5.06B | $7.97B | -10.1% |
| Depreciation & amortisation | $5.68B | $3.59B | $4.43B | $3.11B | +58.3% |
| Change in working capital | $1.79B | -$615.00M | $413.00M | -$794.00M | +391.9% |
| Operating cash flow | $10.75B | $9.08B | $10.26B | $10.53B | +18.4% |
| Capital expenditure | -$3.54B | -$3.19B | -$2.91B | -$2.10B | -10.7% |
| Investing cash flow | -$2.45B | -$4.41B | -$6.20B | -$2.08B | +44.5% |
| Share buybacks | -$5.03B | -$302.00M | -$593.00M | -$497.00M | -1,565.6% |
| Dividends paid | -$4.77B | -$4.70B | -$4.45B | -$4.17B | -1.4% |
| Financing cash flow | -$8.21B | -$5.76B | -$8.05B | -$5.82B | -42.4% |
| Free cash flow | $7.21B | $5.89B | $7.35B | $8.42B | +22.5% |
| End cash position | $7.66B | $7.44B | $8.71B | $12.74B | +2.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $12.30B | $11.24B | $12.21B | $13.17B | $10.73B | +9.4% |
| Operating revenue | $11.60B | $10.51B | $11.30B | $12.43B | $9.99B | +10.4% |
| Cost of revenue | $3.02B | $3.14B | $3.76B | $3.41B | $2.99B | -3.9% |
| Gross profit | $9.28B | $8.11B | $8.45B | $9.76B | $7.74B | +14.5% |
| Research & development | $2.23B | $1.75B | $2.29B | $1.83B | $1.91B | +27.8% |
| Selling, general & admin | $2.63B | $2.49B | $3.44B | $2.29B | $2.46B | +5.6% |
| Total operating expense | $6.90B | $5.84B | $6.82B | $5.97B | $5.80B | +18.2% |
| Operating income | $2.38B | $2.27B | $1.63B | $3.79B | $1.94B | +5.1% |
| Net interest income | -$210.00M | -$118.00M | $161.00M | -$113.00M | -$50.00M | -78.0% |
| Pre-tax income | $837.00M | $2.00B | -$917.00M | $3.51B | $1.42B | -58.2% |
| Tax provision | $451.00M | $420.00M | -$348.00M | $680.00M | $230.00M | +7.4% |
| Net income | $343.00M | $1.61B | -$801.00M | $2.80B | $3.94B | -78.7% |
| Net income to common | $343.00M | $1.61B | -$801.00M | $2.80B | $3.94B | -78.7% |
| Basic EPS | 0.15 | 0.67 | -0.33 | 1.15 | 1.62 | -78.4% |
| Diluted EPS | 0.15 | 0.67 | -0.33 | 1.15 | 1.62 | -78.4% |
| EBIT | $1.12B | $2.18B | -$879.00M | $3.74B | $1.57B | -48.5% |
| EBITDA | $1.68B | $2.72B | -$341.00M | $4.20B | $1.95B | -38.3% |
| Basic shares | 2.39B | 2.41B | 2.43B | 2.44B | 2.43B | -0.6% |
| Diluted shares | 2.39B | 2.41B | 2.43B | 2.44B | 2.43B | -0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.35B | $5.54B | $7.66B | $8.91B | $15.36B | +14.5% |
| Cash & short-term investments | $6.35B | $5.54B | $8.47B | $8.91B | $15.36B | +14.5% |
| Accounts receivable | $8.71B | — | $8.41B | — | $7.81B | — |
| Inventory | $24.12B | $23.50B | $10.21B | $24.50B | $9.62B | +2.6% |
| Total current assets | $31.52B | $30.16B | $30.95B | $34.04B | $37.02B | +4.5% |
| Property, plant & equipment | $11.95B | $11.67B | $11.51B | $11.18B | $11.01B | +2.4% |
| Goodwill & intangibles | $68.31B | $69.09B | $67.56B | $68.87B | $60.71B | -1.1% |
| Total assets | $129.06B | $128.02B | $126.81B | $129.79B | $124.96B | +0.8% |
| Total current liabilities | $31.93B | $30.01B | $28.34B | $32.10B | $29.06B | +6.4% |
| Current debt | $7.03B | $5.92B | $4.34B | $8.20B | $7.31B | +18.7% |
| Long-term debt | $14.65B | $12.30B | $14.25B | $11.70B | $13.20B | +19.1% |
| Total debt | $23.58B | $20.02B | $20.33B | $21.75B | $22.29B | +17.8% |
| Total liabilities | $59.49B | $54.88B | $55.09B | $56.26B | $54.68B | +8.4% |
| Shareholder equity | $69.21B | $72.81B | $71.38B | $73.26B | $70.01B | -4.9% |
| Working capital | -$408.00M | $156.00M | $2.61B | $1.94B | $7.96B | -361.5% |
| Net tangible assets | $894.00M | $3.72B | $3.81B | $4.40B | $9.29B | -76.0% |
| Shares issued | 1.23B | 1.21B | 1.22B | 1.23B | 1.23B | +1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Operating cash flow | $2.96B | $1.68B | $3.44B | $3.75B | $1.46B | +75.9% |
| Investing cash flow | -$365.00M | -$2.28B | -$2.13B | -$9.04B | $9.50B | +84.0% |
| Financing cash flow | -$1.80B | -$1.53B | -$2.57B | -$1.15B | -$3.90B | -18.2% |
| Free cash flow | $1.66B | $1.68B | -$93.00M | $3.75B | $1.46B | -1.1% |
| End cash position | $6.35B | $5.54B | $7.66B | $8.91B | $15.36B | +14.5% |
Options analytics
Put / call volume
0.09
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
27.50
-30.5% from spot
ATM implied vol
1.6%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
2.54K
Contracts, this expiry
Put volume
220
Contracts, this expiry
Heaviest call OI
30.00
0 contracts
Heaviest put OI
27.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.14 | 1.20 | +5.6% |
| Mar 2026 | 1.03 | 1.10 | +7.3% |
| Dec 2025 | 0.85 | 0.91 | +7.4% |
| Sep 2025 | 1.57 | 1.69 | +8.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.56 | 2 | $13.14B | +5.7% |
| Next quarter | 1.12 | 2 | $12.53B | +10.9% |
| Current year | 5.02 | 6 | $47.68B | +9.3% |
| Next year | 5.40 | 6 | $50.65B | +6.2% |
Analyst targets & ownership
Mean target$53.72
High target$63.00
Low target$45.00
Implied upside34.71%
Analyst count9
ConsensusBUY
Strong buy / Buy0 / 5
Hold5
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions8.02%
Institutions holding847
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
40.65
-1.90% from price
SMA 20
41.69
-5.11% from price
SMA 50
43.22
-8.47% from price
SMA 100
43.33
-7.96% from price
SMA 200
44.97
-12.02% from price
EMA 12
40.85
-2.37% from price
EMA 26
41.88
-4.77% from price
EMA 50
42.67
-6.53% from price
RSI (14)
27.3
Oversold
MACD (12,26,9)
-1.03
Hist -0.21
ATR (14)
0.75
1.90% of price
Realised vol 30D
16.4%
Annualised
Bollinger upper
44.03
20, 2σ
Bollinger lower
39.35
20, 2σ
50 / 200 cross
Death
43.22 vs 44.97
Trend bias
Below 200
-12.02%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.32
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
16.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-24.5%
Peak to trough
Max drawdown 5Y
-35.2%
Peak to trough
ATR 14
0.75
1.90% of price
Beta (reported)
0.28
5Y monthly, from filing
Short interest
Shares short
9.30M
Prior 7.32M
Change vs prior
+27.1%
Shorts adding
% of float
0.44%
Normal
% of shares out
0.39%
Against total outstanding
Days to cover
4.3
Liquid
Float
2.16B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 16, 26 | UBS | DOWNGRADE | Buy | Neutral |
| Jan 6, 26 | Barclays | DOWNGRADE | Overweight | Equal-Weight |
| Dec 9, 25 | Guggenheim | DOWNGRADE | Buy | Neutral |
| Dec 8, 25 | JP Morgan | DOWNGRADE | Overweight | Neutral |
| Sep 8, 25 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
| Sep 2, 25 | Deutsche Bank | UPGRADE | Hold | Buy |
| Aug 8, 25 | JP Morgan | UPGRADE | Neutral | Overweight |
| Mar 21, 25 | Goldman Sachs | INITIATED | — | Neutral |
| Jul 26, 24 | Argus Research | MAINTAINED | Buy | Buy |
| Jan 23, 24 | Morgan Stanley | INITIATED | — | Equal-Weight |
| Mar 27, 23 | Argus Research | MAINTAINED | — | Buy |
| Aug 12, 22 | Deutsche Bank | UPGRADE | Sell | Hold |
Dividends & splits
Forward rate$2.42 / yr
Forward yield6.11%
5-year avg yield4.01%
Payout ratio127.51%
Ex-dividend dateMay 4, 2026
Next pay dateJun 3, 2026
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-10-01
Corporate Changes & Voting Matters
6-K · 2026-09-17
Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX
N-PX · 2026-08-25
Corporate Changes & Voting Matters
6-K · 2026-08-06
Corporate Changes & Voting Matters
6-K · 2026-07-30
Corporate Changes & Voting Matters
6-K · 2026-07-27
Corporate Changes & Voting Matters
6-K · 2026-07-17
Corporate Changes & Voting Matters
6-K · 2026-07-07
Headlines
Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)
Simply Wall St. · 11h ago
Health Care Roundup: Market Talk
The Wall Street Journal · 12h ago
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
Zacks · 1d ago
Press Release : Availability of the aide-mémoire for Q3 2026 results
GlobeNewswire · 1d ago
Housekeeping Starts with Branding: Vicapsys Life Sciences Adopts New Corporate Identity Developed by FutureBrand for Vicapsys and Its Stateline Subsidiary
ACCESS Newswire · 2d ago
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
Stocktwits · 4d ago
An $8 Billion Reason Why Regeneron Stock Is in Focus
Barchart · 5d ago
Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®
PR Newswire · 5d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.